While studies have demonstrated the improved therapeutic efficacy of BDNF through enhanced brain deposition using BBBM peptides in mouse models of multiple sclerosis (MS) and Alzheimer’s disease (AD) [117,118], no investigations have been conducted to determine the therapeutic impact of enhanced antibody brain deposition achieved with these peptides. Here, BDNF is linked to Alzheimer disease.